Drugs / TherVacB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05727267 | Jan 2024 → May 2026 | chronic hepatitis B virus infection | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TherVacB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05727267 ↗ |
| Modality | Vaccine | “A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate” NCT05727267 ↗ |